A nurse is meeting with a client and their family at a local treatment clinic. The client's partner demands to see the client's records and treatment plan, and states they need to be responsible for overseeing the treatment. The client's partner reports that their own health has deteriorated since caring for the client. The nurse should recognize that the client's partner is displaying which of the following behaviors?

C. Psychiatric pharmacogenomic testing involves analyzing an individual's genetic makeup to predict their response to psychiatric medications. This testing provides healthcare providers with information about how an individual's genetic variations may impact their metabolism of medications.

A. Psychiatric pharmacogenomic testing can inform treatment decisions but it does not determine the likelihood of a cure. Mental illness is complex and often requires multimodal treatment approaches beyond medication alone.

B. Pharmacogenomic testing can provide information about how an individual's genetics may interact with specific medications but it primarily focuses on identifying which medications are likely to be most effective for the individual, rather than interactions between medications.

D. Psychiatric pharmacogenomic testing does not determine the cause of mental illness. Mental illnesses are multifactorial and have complex etiologies involving genetic, biological, environmental, and psychosocial factors.

C. Agranulocytosis is a serious side effect associated with clozapine, an antipsychotic medication. Agranulocytosis is characterized by a severe reduction in the number of white blood cells (specifically granulocytes) in the bloodstream, leading to an increased risk of infection. The client should be educated to monitor for signs and symptoms of agranulocytosis, including sore throat, fever, chills, and muscle aches, as these may indicate an underlying infection due to neutropenia.

A. Severe restlessness may be a side effect of some antipsychotic medications, but it is not specifically associated with agranulocytosis.

B. Respiratory depression and a comatose state are not typical manifestations of agranulocytosis.

D. Increased anxiety and suicidal ideations may be symptoms of certain mental health conditions or adverse effects of psychiatric medications, but they are not characteristic of agranulocytosis.